Novartis Investigative Site

Chalcis GR 341 00

0 studies enrolling now · 3 studies all time

What they study most

Atherosclerosis, Cardiovascular Disease and Lipoprotein(a)

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed